Business Wire

RI-HASBRO

10.9.2019 15:02:09 CEST | Business Wire | Press release

Share
Hasbro Introduces Ms. Monopoly – First Game in the Franchise that Celebrates Women Trailblazers

Today, Hasbro, Inc. is introducing the first-ever game in the Monopoly franchise that celebrates women trailblazers with Ms. Monopoly. The Ms. Monopoly game marks the first time in the franchise’s history where a new character will grace the cover – and while Mr. Monopoly is a real-estate mogul, Ms. Monopoly is an advocate whose mission is to invest in female entrepreneurs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005160/en/

Ms. Monopoly was created to inspire everyone, young and old as it spotlights women who have challenged the status quo. To celebrate, in lieu of Monopoly winnings, Hasbro surprised young female inventors and entrepreneurs with the recognition they deserve –approximately $20,580 in REAL money to fuel their inventive spirit and further their projects – which just so happens to be the same amount of Monopoly money featured in the game. You can see all of their reactions to the surprise here . All of the young inventors come from very different backgrounds, but with a common goal to help others using their inventions:

  • Sophia Wang, a 16-year-old from Connecticut invented a device that can detect sinkholes before they occur, and after two years of work, her prototype is now 93% accurate. She is hoping to get it patented and in the hands of communities in Florida that are vulnerable to sinkholes.
  • Gitanjali Rao, a 13-year-old from Denver came up with an invention that helps detect lead in drinking water so that individuals can do the test themselves and get results sooner. Her goal is to create an inexpensive, easy to use, portable device so that people all around the world can use it.
  • Ava Canney, a 16-year-old from Ireland, invented a spectrometer that measures the amount of dye in candy and soda. After studying the harmful effects of additives in our food, Ava set out to help people make educated decisions about the toxins they put into their bodies.

“Through the introduction of Ms. Monopoly and the money these young women have received to invest in their future projects, we want to recognize and celebrate the many contributions women have made to our society and continue to make on a daily basis,” said Jen Boswinkel, Senior Director, Global Brand Strategy and Marketing, Hasbro.

Hitting shelves in mid-September, Ms. Monopoly gives new meaning to the franchise, as properties are replaced by groundbreaking inventions and innovations made possible by women throughout history and instead of building houses, you build business headquarters. From inventions like WiFi to chocolate chip cookies, solar heating and modern shapewear, Ms. Monopoly celebrates everything from scientific advancements to everyday accessories – all created by women.

Ms. Monopoly is also the first-ever game where women make more than men – a fun spin in the game that creates a world where women have an advantage often enjoyed by men. However, if men play their cards right, they can make more money too.

Ms. Monopoly is available for pre-order now at Walmart and will be available at most major retailers nationwide and in select countries globally starting September 2019 for a suggested retail price of $19.99.

About Hasbro
Hasbro (NASDAQ: HAS) is a global play and entertainment company committed to Creating the World's Best Play Experiences. From toys and games to television, movies, digital gaming and consumer products, Hasbro offers a variety of ways for audiences to experience its iconic brands, including NERF, MY LITTLE PONY, TRANSFORMERS, PLAY-DOH, MONOPOLY, BABY ALIVE, MAGIC: THE GATHERING and POWER RANGERS, as well as premier partner brands. Through its entertainment labels, Allspark Pictures and Allspark Animation, the Company is building its brands globally through great storytelling and content on all screens. Hasbro is committed to making the world a better place for children and their families through corporate social responsibility and philanthropy. Hasbro ranked No. 13 on the 2019 100 Best Corporate Citizens list by CR Magazine , and has been named one of the World’s Most Ethical Companies® by Ethisphere Institute for the past eight years. Learn more at www.hasbro.com , and follow us on Twitter (@Hasbro ) and Instagram (@Hasbro ).

HAS-B

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye